Skip to main content

Advertisement

Log in

Notch3 overexpression associates with poor prognosis in human non-small-cell lung cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

An Erratum to this article was published on 05 September 2013

Abstract

Notch3 receptor is one of the mammalian Notch family receptors (Notch1–4) which plays an important role in the regulation of cellular proliferation, differentiation, and apoptosis. Overexpression of Notch3 is associated with tumorigenesis. In order to assess the expression of Notch3 in Chinese non-small-cell lung cancer (NSCLC) patients and determine its association with prognosis, we designed a prospective study with five years of follow-up to evaluate Notch3 expression in NSCLC tissues and adjacent non-cancerous normal lung tissues from 131 patients undergoing surgical treatment by immunohistochemistry and western blot analysis. Notch3 had high expression in 67 of 131 cases of NSCLC (51.1 %), which was significantly higher than in adjacent noncancerous lung tissues. Moreover, Notch3 overexpression was significantly correlated with TNM stage (P = 5.41e−07 in squamous cell carcinoma, P = 5.338e−07 in adenocarcinoma) and lymph node metastasis (P = 0.00764 in squamous cell carcinoma, P = 0.01491 in adenocarcinoma). Kaplan–Meier survival analysis showed that the overall survival times in patients expressing Notch3 in NSCLC were shorter. Multivariate analysis further demonstrated that Notch3 was an independent prognostic factor for patients with NSCLC. Therefore, Notch3 might be a useful biomarker to predict the prognosis of patients with NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

NSCLC:

Human non-small-cell lung cancer

°C:

Celsius

DAB:

Diaminobenzidine

PBS:

Phosphate-buffered saline

HR:

Hazard ratio

CI:

Confidence interval

PVDF:

Polyvinylidene fluoride

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277–300.

    Article  PubMed  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62(1):10–29.

    Article  PubMed  Google Scholar 

  3. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review 1975–2009 (vintage: populations). Bethesda: National Cancer Institute; 2009.

    Google Scholar 

  4. Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with bevacizumab in non-small cell lung cancer. NEJM. 2006;355(24):2542–50.

    Article  PubMed  CAS  Google Scholar 

  5. Lee SY, Kim MJ, Jin G, et al. Choi somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol. 2010;5(11):1734–40.

    Article  PubMed  Google Scholar 

  6. Casás-Selves M, Kim J, Zhang Z, et al. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 2012;72(16):4154–64.

    Article  PubMed  Google Scholar 

  7. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389–95.

    Article  PubMed  CAS  Google Scholar 

  8. Shawber CJ, Kitajewski J. Notch function in the vasculature: insights from zebrafish, mouse and man. BioEssays. 2004;26:225–34.

    Article  PubMed  CAS  Google Scholar 

  9. Gridley T. Notch signaling during vascular development. Proc Natl Acad Sci USA. 2001;98:5377–8.

    Article  PubMed  CAS  Google Scholar 

  10. Collins BJ, Kleeberger W, Ball DW. Notch in lung development and lung cancer. Semin Cancer Biol. 2004;14:357–64.

    Article  PubMed  CAS  Google Scholar 

  11. Lin L, Mernaugh R, Yi F, et al. Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer. Cancer Res. 2010;70:632–8.

    Article  PubMed  CAS  Google Scholar 

  12. Westhoff B, Colaluca IN, D’Ario G, et al. Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci USA. 2009;106:22293–8.

    Article  PubMed  CAS  Google Scholar 

  13. Baumgart A, Seidl S, Vlachou P, et al. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res. 2010;70:5368–78.

    Article  PubMed  CAS  Google Scholar 

  14. Park JT, Chen X, Trope CG, et al. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol. 2010;177:1087–94.

    Article  PubMed  CAS  Google Scholar 

  15. Rahman MT, Nakayama K, Rahman M, et al. Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer. Am J Clin Pathol. 2012;138(4):535–44.

    Article  PubMed  CAS  Google Scholar 

  16. Jonusiene V, Sasnauskiene A, Lachej N, et al. Down-regulated expression of Notch signaling molecules in human endometrial cancer. Med Oncol. 2013;30(1):438.

    Article  PubMed  Google Scholar 

  17. Yao J, Qian C. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway. Med Oncol. 2010;27(3):1017–22.

    Article  PubMed  CAS  Google Scholar 

  18. Mann CD, Bastianpillai C, Neal CP, et al. Notch3 and HEY-1 as prognostic biomarkers in pancreatic adenocarcinoma. PLoS ONE. 2012;7(12):e51119.

    Article  PubMed  CAS  Google Scholar 

  19. Kang H, An HJ, Song JY, et al. Notch3 and Jagged2 contribute to gastric cancer development and to glandular differentiation associated with MUC2 and MUC5AC expression. Histopathology. 2012;61:576–86.

    PubMed  Google Scholar 

  20. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136(1):260–71.

    Article  PubMed  Google Scholar 

  21. Mitsuhashi Y, Horiuchi A, Miyamoto T, et al. Prognostic significance of Notch signalling molecules and their involvement in the invasiveness of endometrial carcinoma cells. Histopathology. 2012;60(5):826–37.

    Article  PubMed  Google Scholar 

  22. Yeasmin S, Nakayama K, Rahman MT, et al. Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes. Gynecol Oncol. 2010;117:409–16.

    Article  PubMed  CAS  Google Scholar 

  23. Ma D, Dong X, Zang S, et al. Aberrant expression and clinical correlation of Notch signaling molecules in breast cancer of Chinese population. Asia Pac J Clin Oncol. 2011;7(4):385–91.

    Article  PubMed  Google Scholar 

  24. Shah MM, Zerlin M, Li BY, et al. The role of notch and gamma-secretase inhibition in an ovarian cancer model. Anticancer Res. 2013;33(3):801–8.

    PubMed  CAS  Google Scholar 

  25. Chen X, Thiaville MM, Chen L, et al. Defining NOTCH3 target genes in ovarian cancer. Cancer Res. 2012;72(9):2294–303.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was funded by Key Programs of Educational Commission of Anhui Province (No. KJ2011A178) and Natural Science Foundation of Science and Technology Department of Anhui Province (No. 1208085MH146).

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yan-bei Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ye, Yz., Zhang, Zh., Fan, Xy. et al. Notch3 overexpression associates with poor prognosis in human non-small-cell lung cancer. Med Oncol 30, 595 (2013). https://doi.org/10.1007/s12032-013-0595-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0595-7

Keywords

Navigation